Retatrutide vs Semaglutide: 24% vs 15% Weight Loss Compared

Retatrutide and semaglutide are the two ends of the metabolic-peptide spectrum: the newest, highest-efficacy triple agonist against the most established single-receptor GLP-1 compound. The comparison comes up constantly, so here is the evidence side by side.

This is written for research and educational purposes. It reports published trial data; it is not medical advice, and these compounds are research materials, not approved medications.

The numbers, side by side

Why retatrutide's number is bigger: the mechanism

The efficacy gap is not a formulation trick — it is receptor coverage. Semaglutide is a pure GLP-1 agonist: it suppresses appetite, slows gastric emptying, and improves glucose handling through a single receptor. Retatrutide keeps all of that and adds two more arms. GIP appears to amplify GLP-1's effects, and glucagon adds an energy-expenditure mechanism that works on the output side of energy balance rather than only reducing intake. ^[3]

In other words, semaglutide works on one lever; retatrutide works on three complementary ones. The triple-agonist mechanism guide breaks down exactly what each receptor contributes.

Side effects: more alike than different

Both compounds are dominated by the same tolerability story: gastrointestinal effects — nausea, diarrhea, constipation, reduced appetite — that are dose-dependent and cluster during dose escalation, then ease at a stable dose. This is a GLP-1-class signature, and both use gradual titration to manage it. ^[1]

The one notable difference is that retatrutide's trial data reported a skin-sensation effect (dysesthesia) at higher doses that is not a prominent feature of semaglutide's profile. As always, these are trial-reported findings, not individual predictions.

Dosing and half-life

The two are more alike than different here. Both are once-weekly subcutaneous compounds, and both have multi-day half-lives — retatrutide ~6 days, semaglutide ~7 days — which is what makes weekly dosing viable and means both take about a month of accumulation to reach steady state. Both escalate the dose stepwise. If you understand one compound's cadence, you understand the other's; the half-life guide covers the pharmacokinetics that apply to both.

What the response rates showed

Averages can hide wide variation, so the more revealing question is how consistently each compound worked. Semaglutide's STEP 1 trial reported that a large majority of participants crossed meaningful thresholds — roughly 86% reached at least 5% loss, about 69% reached 10%, and about half reached 15%. ^[2] Retatrutide's Phase 2 data reported an even tighter, higher-responding distribution at the top doses, with the large majority of participants reaching clinically meaningful loss. ^[1]

The practical read for a research program is that both compounds are reliable in the sense that most subjects respond; they differ in how far that response goes.

Cost, availability, and data maturity

Beyond efficacy, three practical factors separate them. Data maturity: semaglutide has years of characterization and post-trial data behind it; retatrutide is newer, with the Phase 3 program still maturing — so there is simply more known about semaglutide over long horizons. Availability: both are investigational research compounds in this context and are sourced the same way, so neither has a practical access advantage over the other. Cost: pricing tracks sourcing rigor more than the molecule itself — an independently tested, batch-matched vial of either compound costs more than an untested one, and that difference is the price of knowing what is in it.

Which to choose for research

The honest answer is that they serve different purposes. Semaglutide is the established reference — the single-receptor compound with the deepest characterization and the longest track record, which makes it the natural baseline. Retatrutide is the efficacy frontier — the newest mechanism and the largest trial effect, which makes it the compound to study when the question is about maximal incretin-plus-glucagon response.

If the research goal is peak effect and the novel triple mechanism, retatrutide is the obvious subject. If it is a well-characterized single-receptor benchmark, semaglutide remains the standard. Many programs study both precisely to map the gap between them. For the full picture on retatrutide specifically, see the complete retatrutide guide.

A note on comparing across separate trials

One caveat deserves emphasis because it is the most common way this comparison gets overstated: the 24.2% and ~15% figures come from different trials, with different participants, durations, and designs. Semaglutide's STEP 1 ran 68 weeks; retatrutide's Phase 2 measured at 48 weeks. ^{[1] [2]} No published head-to-head study has put the two compounds against each other directly. The mechanism gives strong reason to expect retatrutide to lead — three complementary receptors versus one — and the separate-trial numbers point the same way. But "expected to lead based on mechanism and separate trials" is a more honest framing than treating the two percentages as if they came from the same experiment. That distinction is exactly the kind of precision that separates a credible source from a hype one, and it is worth holding onto when you read any cross-compound comparison.

For research and educational purposes only. Not medical advice. Weight-loss figures are drawn from separate clinical trials, not a head-to-head comparison. These compounds are research materials and are not approved for human use.